← Eichor
Study identifier: NCT05086692 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Beta-only IL-2 ImmunoTherapY Study

Condition: Advanced Solid Tumor · Unresectable Solid Tumor · Clear Cell Renal Cell Carcinoma  ·  Sponsor: Medicenna Therapeutics, Inc.

PhasePhase 1/Phase 2
Planned participants115
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Nina Merchant  ·  604-340-3081  ·  nmerchant@medicenna.com

Melissa Coello  ·  267-476-2313  ·  mcoello@medicenna.com

Always discuss trial participation with your own doctor first.

Locations (27)

Sharp Memorial HospitalSan Diego, California, United StatesRecruiting
UCSF Helen Diller Family Comprehensive Cancer CenterSan Francisco, California, United StatesActive Not Recruiting
Providence Saint John's Health CenterSanta Monica, California, United StatesRecruiting
Boca Raton Regional HospitalBoca Raton, Florida, United StatesRecruiting
Emory - Winship Cancer InstituteAtlanta, Georgia, United StatesRecruiting
Karmanos Cancer InstituteDetroit, Michigan, United StatesRecruiting
MD Anderson Cancer CenterHouston, Texas, United StatesActive Not Recruiting
Scientia Clinical ResearchRandwick, New South Wales, AustraliaRecruiting
Macquarie UniversitySydney, New South Wales, AustraliaRecruiting
University of the Sunshine CoastBuderim, Queensland, AustraliaRecruiting
Gallipoli Medical Research FoundationGreenslopes, Queensland, AustraliaRecruiting
Princess Margaret Cancer CenterToronto, Ontario, CanadaRecruiting

+ 15 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05086692